Biotechnology

Bloomage Joins the United Nations Global Compact

PARSIPPANY, N.J., Jan. 27, 2025 /PRNewswire/ -- Bloomage, a global leader in hyaluronic acid and other bioactive innovations, officially joined the United Nations Global Compact (UNGC). This commitment further reflects Bloomage's on-going efforts in global sustainable development.

2025-01-27 21:00 2798

Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA

HONG KONG, Jan. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE) of the N...

2025-01-27 09:53 2883

Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors

SINGAPORE and PHILADELPHIA, Jan. 24, 2025 /PRNewswire/ -- Nuevocor , an IND-stage biotechnology company dedicated to developing functional cures to treat cardiomyopathies with aberrant mechanobiology, today announces the appointment ofDr. Andreas Wallnöfer as Chairman ...

2025-01-24 22:00 5009

NUS researchers pioneer DNA-tagged gold nanoparticles for targeted cancer treatment

Using DNA barcoding, the novel technique tracks and optimises gold nanoparticles for precise drug delivery to tumours, advancing cancer therapies that are safer and more effective SINGAPORE, Jan. 24, 2025 /PRNewswire/ -- A team of researchers from the National University of Singapore (NUS) has d...

2025-01-24 15:55 3270

Kexing Biopharm Participates in the 17th Biotech Showcase, with Multiple Innovation Pipelines Gaining Attention

SHENZHEN, China, Jan. 24, 2025 /PRNewswire/ -- From January 13 to 16, Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase Conference inSan Francisco and the Global Biopharma Symposium hosted by Jones Day & MSQ Ventures. The Jones...

2025-01-24 14:59 3216

GI Innovation-LaNova Medicines Signs MOU for GI-102 + ADC Pancreatic Cancer Combination Therapy

SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- GI Innovation  (KQ:358570) announced that it signed a Memorandum of Understanding (MOU) with LaNova Medicines (LaNova) for the development of GI-102 and ADC pancreatic cancer combination therapy.

2025-01-22 21:00 3308

L&C Bio Secures World's First NMPA Approval for 'MegaDerm Plus' in China

SEONGNAM-SI, South Korea, Jan. 22, 2025 /PRNewswire/ -- L&C Bio (CEO Hwan-Chul Lee) has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval fromChina's National Medical Products Administration (NMPA) for its acellular dermal ma...

2025-01-22 20:30 3043

Samsung Biologics reports fourth quarter and fiscal year 2024 financial results

* Recorded Q4'24 consolidated revenue of KRW 1.26 trillion * Recorded FY'24 consolidated revenue of KRW 4.55 trillion * Poised for further growth with expanded capacity and new service offerings INCHEON,South Korea, Jan. 22, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a globa...

2025-01-22 15:06 2640

Akeso Received Payment for the Development Collaboration on Tagitanlimab

HONG KONG, Jan. 22, 2025 /PRNewswire/ -- On January 22, 2025, Akeso Inc. (9926.HK) announced that it had received payment from Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. ("Sichuan Kelun") for their collaboration on the development of tagitanlimab, an innovative humanized monoclona...

2025-01-22 14:57 3533

Hyundai ADM Unveils a "New Paradigm in Cancer Treatment" - Preclinical Study Shows Promise for Continuous Oral Chemotherapy with Lowered Side Effects Risks

SEOUL, South Korea, Jan. 22, 2025 /PRNewswire/ -- Hyundai ADM Bio (Co-CEOs Taek-Sung Kim and Kwang-Hee Kim) announced the results of its preclinical study on the oral anti-cancer drug OTX-M, developed from the well-known injectable chemotherapy drug docetaxel, at the "Biotech Showcase 2025" held ...

2025-01-22 14:43 2342

Anbio Biotechnology to Showcase Cutting-Edge Diagnostic Solutions at 2025 Medlab Middle East

DUBAI, UAE , Jan. 21, 2025 /PRNewswire/ -- Anbio Biotechnology ("Anbio"), a global leader in in-vitro diagnostic technologies, is excited to announce its participation in the 2025 Medlab Middle East exhibition, taking place from 3rd to 6th February at theDubai World Trade Centre. The event is one...

2025-01-22 13:08 2262

Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025

BOSTON, Jan. 21, 2025 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced the presentation of latest data from its Phase I/II CLINCH study ongoing in China and Australia evaluating ATN-022 (CLDN18.2 antibody-drug conjugate [ADC]) in patients with advance...

2025-01-22 11:01 2429

YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia

SHANGHAI, Jan. 20, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial forYOLT-204, an investigational therapy for the treatment of transfusion-dependent beta-thalassemia (TDT). TDT i...

2025-01-21 10:34 2917

Origin Agritech Held Transgenic Breeding Seminar and Announces Partnerships with 12 Leading Agricultural Companies

BEIJING, Jan. 17, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced the signing of cooperation agreements (the "agreements") with 12 prominent agricultural companies, including Beidahuang Kenfen...

2025-01-17 21:30 8712

Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer

SHANGHAI, Jan. 16, 2025 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that Senaparib Capsules (派舒宁®)has received marketing authorizatio...

2025-01-17 10:56 2516

LOTTE BIOLOGICS to Present at the 2025 J.P. Morgan Healthcare Conference

* New CEO James Park Delivers First Presentation at J.P. Morgan Healthcare Conference on "Advancing as a Global CDMO Leader" * Unveiling of Next-Generation ADC Platform 'SoluFlex Link': Enabling High-Potency, High-Yield ADC Development and Manufacturing * Incheon Songdo Bio Campus Plant 1 Un...

2025-01-17 07:11 3021

Origin Agritech Showcases Advanced Biotechnology Capabilities and Announces Landmark Partnership at International Seed Industry Conference

SANYA, China, Jan. 16, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced significant advances in its biotechnology breeding program and a groundbreaking partnership during the 4th Sanya Internat...

2025-01-16 21:59 4486

NEXTBIOMEDICAL Receives IDE Approval from FDA for Nexsphere-F™, an Embolic Microsphere for Use in Genicular Artery Embolization (GAE) for Knee Osteoarthritis: The U.S. RESORB Trial Launches

SEOUL, South Korea, Jan. 15, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD, a KOSDAQ-listed innovative medical device company inSouth Korea, proudly announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for its clinical tria...

2025-01-15 22:00 3287

Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

* Celltrion unveils strategic roadmap for the first time outlining its innovative drug development strategy and its plan to submit 13 Investigational New Drug (IND) application by 2028 * Company reinforces its commitment to a two-pillar growth strategy focusing on its groundbreaking new drug ...

2025-01-15 10:52 2702

ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS

SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil (development code name PF1804),' a treatment for DMD (Duchenne Muscular Dystrophy) cardiomyopathy, from the U.S. Food and Drug Administration...

2025-01-14 21:00 2773
1 ... 33343536373839 ... 156